|

A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

RECRUITINGSponsored by Novartis Pharmaceuticals
Actively Recruiting
SponsorNovartis Pharmaceuticals
Started2026-06-30
Est. completion2026-11-30
Eligibility
Age18 Years – 115 Years
SexMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07677254

Summary

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Eligibility

Age: 18 Years – 115 YearsSex: MALEHealthy volunteers accepted
Inclusion criteria:

* Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
* Male sex at index, where index is the date of initial mCRPC diagnosis.
* Age 18 years at index.

Exclusion criteria:

• None

Conditions2

CancerProstatic Neoplasms, Castration-Resistant

Locations1 site

Novartis
East Hanover, New Jersey, 07936

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.